ARS Pharmaceuticals (SPRY) Times Interest Earned (2026)

ARS Pharmaceuticals has reported Times Interest Earned for 7 years, with the latest figure at -$1.69 in Q1 2026.

• Quarterly Times Interest Earned rose 99.95% year-over-year to -$1.69 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.69 (up 99.77% YoY) and the FY2025 annual result came in at -$2.3, down 5224.51% from the prior year.
• Times Interest Earned climbed to -$1.69 in Q1 2026 per SPRY's latest filing, from -$18.98 in the prior quarter.
• Over five years, Times Interest Earned peaked at -$0.0 in Q1 2023 and troughed at -$3379.7 in Q1 2025.
• A 5-year average of -$238.52 and a median of -$0.83 in 2022 frame the typical range for Times Interest Earned.
• The sharpest annual moves came in 2023 and 2025: Times Interest Earned surged 99.97% in 2023, then plunged 1986412.08% in 2025.
• Over 5 years, Times Interest Earned stood at -$154.43 in 2022, then jumped by 100.0% to -$0.0 in 2023, then slumped by 22032750.92% to -$256.51 in 2024, then surged by 92.6% to -$18.98 in 2025, then soared by 91.09% to -$1.69 in 2026.
• According to Business Quant data, Times Interest Earned over the past three periods registered -$1.69, -$18.98, and -$0.89 for Q1 2026, Q4 2025, and Q3 2025 respectively.